Free Trial

Madrigal Pharmaceuticals (MDGL) Competitors

Madrigal Pharmaceuticals logo
$288.00 +5.14 (+1.82%)
As of 12:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDGL vs. BIIB, UTHR, INCY, BMRN, EXEL, NBIX, EXAS, RGEN, HALO, and IONS

Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.

Madrigal Pharmaceuticals vs.

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.82B1.80$1.63B$10.1311.88
Madrigal Pharmaceuticals$317.38M19.79-$373.63M-$18.05-15.67

Biogen received 1358 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 68.03% of users gave Madrigal Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
BiogenOutperform Votes
1824
71.28%
Underperform Votes
735
28.72%
Madrigal PharmaceuticalsOutperform Votes
466
68.03%
Underperform Votes
219
31.97%

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.91, suggesting that its stock price is 191% less volatile than the S&P 500.

In the previous week, Biogen had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 18 mentions for Biogen and 16 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.37 beat Biogen's score of 1.19 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
12 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Madrigal Pharmaceuticals
12 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen16.87% 14.98% 8.76%
Madrigal Pharmaceuticals N/A -71.78%-53.25%

Biogen currently has a consensus target price of $191.30, suggesting a potential upside of 58.92%. Madrigal Pharmaceuticals has a consensus target price of $416.33, suggesting a potential upside of 47.19%. Given Biogen's higher probable upside, equities research analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
20 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.38
Madrigal Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Summary

Biogen beats Madrigal Pharmaceuticals on 13 of the 18 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDGL vs. The Competition

MetricMadrigal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.28B$6.24B$5.21B$8.44B
Dividend YieldN/A3.01%4.99%4.18%
P/E Ratio-11.288.6526.4719.72
Price / Sales19.79268.82397.91117.74
Price / CashN/A65.8538.3134.62
Price / Book13.786.266.694.51
Net Income-$373.63M$143.73M$3.22B$247.94M
7 Day Performance-5.58%-0.38%0.06%3.40%
1 Month Performance-11.91%4.55%5.41%11.07%
1 Year Performance33.59%-7.57%13.19%5.78%

Madrigal Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDGL
Madrigal Pharmaceuticals
4.6339 of 5 stars
$288.00
+1.8%
$416.33
+44.6%
+34.1%$6.39B$317.38M-11.4790Positive News
BIIB
Biogen
4.8959 of 5 stars
$121.80
-1.4%
$194.56
+59.7%
-46.9%$17.83B$9.68B10.888,720
UTHR
United Therapeutics
4.9889 of 5 stars
$298.70
+1.4%
$392.00
+31.2%
+11.1%$13.47B$2.99B13.12980Positive News
INCY
Incyte
4.9136 of 5 stars
$62.11
-0.7%
$73.53
+18.4%
+7.2%$12.02B$4.41B230.052,320News Coverage
Positive News
BMRN
BioMarin Pharmaceutical
4.9941 of 5 stars
$62.06
+0.0%
$93.45
+50.6%
-26.3%$11.84B$2.95B28.213,080Positive News
EXEL
Exelixis
4.1118 of 5 stars
$39.84
+0.6%
$37.59
-5.7%
+112.7%$10.98B$2.17B22.511,220Analyst Forecast
Options Volume
News Coverage
Positive News
NBIX
Neurocrine Biosciences
4.9321 of 5 stars
$109.75
+0.1%
$160.90
+46.6%
-14.2%$10.86B$2.36B33.361,200
EXAS
Exact Sciences
4.7055 of 5 stars
$53.33
+3.5%
$70.90
+32.9%
+1.6%$10.06B$2.83B-9.576,400Positive News
RGEN
Repligen
4.9047 of 5 stars
$140.92
-0.4%
$173.25
+22.9%
-25.8%$7.91B$650.43M-276.312,020
HALO
Halozyme Therapeutics
4.9697 of 5 stars
$60.62
-0.9%
$62.89
+3.7%
+9.3%$7.49B$1.02B17.67390Analyst Downgrade
IONS
Ionis Pharmaceuticals
4.5031 of 5 stars
$33.65
+2.7%
$56.67
+68.4%
-14.8%$5.35B$705.14M-11.07800Positive News

Related Companies and Tools


This page (NASDAQ:MDGL) was last updated on 5/15/2025 by MarketBeat.com Staff
From Our Partners